{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:33:38Z","timestamp":1740126818994,"version":"3.37.3"},"reference-count":85,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adrenocortical carcinoma (ACC) is a malignant carcinoma with an extremely poor\n                    prognosis, and its pathogenesis remains to be understood to date, necessitating\n                    further investigation. This study aims to discover biomarkers and potential\n                    therapeutic agents for ACC through bioinformatics, enhancing clinical diagnosis\n                    and treatment strategies. Differentially expressed genes (DEGs) between ACC and\n                    normal adrenal cortex were screened out from the GSE19750 and GSE90713 datasets\n                    available in the GEO database. An online Venn diagram tool was utilized to\n                    identify the common DEGs between the two datasets. The identified DEGs were\n                    subjected to functional assessment, pathway enrichment, and identification of\n                    hub genes by performing the protein-protein interaction (PPI), Gene Ontology\n                    (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The\n                    differences in the expressions of hub genes between ACC and normal adrenal\n                    cortex were validated at the GEPIA2 website, and the association of these genes\n                    with the overall patient survival was also assessed. Finally, on the QuartataWeb\n                    website, drugs related to the identified hub genes were determined. A total of\n                    114 DEGs, 10 hub genes, and 69 known drugs that could interact with these genes\n                    were identified. The GO and KEGG analyses revealed a close association of the\n                    identified DEGs with cellular signal transduction. The 10 hub genes identified\n                    were overexpressed in ACC, in addition to being significantly associated with\n                    adverse prognosis in ACC. Three genes and the associated known drugs were\n                    identified as potential targets for ACC treatment.<\/jats:p>","DOI":"10.1055\/a-2209-0771","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T23:47:38Z","timestamp":1702943258000},"page":"593-603","source":"Crossref","is-referenced-by-count":0,"title":["Identification of Key Genes and Related Drugs of Adrenocortical\n                    Carcinoma by Integrated Bioinformatics Analysis"],"prefix":"10.1055","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0972-5558","authenticated-orcid":false,"given":"Jian-bin","family":"Wei","sequence":"additional","affiliation":[{"name":"The Third Clinical Medical College, Fujian Medical University, Fuzhou,\n                    China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-chun","family":"Zeng","sequence":"additional","affiliation":[{"name":"The Third Clinical Medical College, Fujian Medical University, Fuzhou,\n                    China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui-rong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhongshan Hospital Xiamen University,\n                    Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhongshan Hospital Xiamen University,\n                    Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-min","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Zhongshan Hospital Xiamen University,\n                    Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"S Zheng","year":"2016","journal-title":"Cancer Cell"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-019-0773-7","article-title":"Management of adrenocortical carcinoma","volume":"21","author":"S Jasim","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/PAP.0000000000000363","article-title":"Histopathologic features of adrenal cortical carcinoma","volume":"30","author":"A Gambella","year":"2023","journal-title":"Adv Anat Pathol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/CCO.0b013e328340d879","article-title":"Toward a pathway-centered approach for the treatment of adrenocortical\n                    carcinoma","volume":"23","author":"K J Bussey","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3892\/or.2017.5427","article-title":"New insights and future perspectives in the therapeutic strategy of\n                    adrenocortical carcinoma","volume":"37","author":"A Stigliano","year":"2017","journal-title":"Oncol Rep"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.suc.2019.04.012","article-title":"Adrenocortical cancer treatment","volume":"99","author":"S E Long","year":"2019","journal-title":"Surg Clin North Am"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1200\/JCO.2002.20.4.941","article-title":"Adrenocortical carcinoma: clinical, morphologic, and molecular\n                    characterization","volume":"20","author":"A Stojadinovic","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"eadd0422","DOI":"10.1126\/sciadv.add0422","article-title":"Sexually dimorphic activation of innate antitumor immunity prevents\n                    adrenocortical carcinoma development","volume":"8","author":"J J Wilmouth","year":"2022","journal-title":"Sci Adv"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3390\/biomedicines9080892","article-title":"Molecular mechanisms of functional adrenocortical adenoma and carcinoma: genetic\n                    characterization and intracellular signaling pathway","volume":"9","author":"H Shimada","year":"2021","journal-title":"Biomedicines"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"931389","DOI":"10.3389\/fendo.2022.931389","article-title":"Disorders of the adrenal cortex: Genetic and molecular aspects","volume":"13","author":"G Pitsava","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/cancers13081798","article-title":"Tumor microenvironment in adrenocortical carcinoma: barrier to immunotherapy\n                    success?","volume":"13","author":"N Georgantzoglou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s12020-017-1506-z","article-title":"Analysis of circulating extracellular vesicle-associated microRNAs in\n                    cortisol-producing adrenocortical tumors","volume":"59","author":"P Perge","year":"2018","journal-title":"Endocrine"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.surg.2016.11.036","article-title":"Overexpression of cytochrome P450 2A6 in adrenocortical carcinoma","volume":"161","author":"T D Murtha","year":"2017","journal-title":"Surgery"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40169-015-0080-3","article-title":"Targeting polo-like kinase 1, a regulator of p53, in the treatment of\n                    adrenocortical carcinoma","volume":"5","author":"K J Bussey","year":"2016","journal-title":"Clin Transl Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"771579","DOI":"10.3389\/fonc.2021.771579","article-title":"EMS1\/DLL4-Notch signaling axis augments cell cycle-mediated\n                    tumorigenesis and progress in human adrenocortical carcinoma","volume":"11","author":"Y G Huang","year":"2021","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e000469","DOI":"10.1136\/jitc-2019-000469","article-title":"Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the\n                    prognosis of adrenocortical carcinoma","volume":"8","author":"L S Landwehr","year":"2020","journal-title":"J Immunother Cancer"},{"key":"ref17","first-page":"1","article-title":"Ubiquitin-specific protease 22 is a deubiquitinase of CCNB1","volume":"1","author":"Z Lin","year":"2015","journal-title":"Cell Discov"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neuropharm.2014.07.014","article-title":"MJ-66 induces malignant glioma cells G2\/M phase arrest and mitotic\n                    catastrophe through regulation of cyclin B1\/Cdk1 complex","volume":"86","author":"W T Liu","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.4161\/cbt.29691","article-title":"Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth\n                    in human colorectal cancer","volume":"15","author":"Y Fang","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.18632\/aging.102254","article-title":"HnRNPR-CCNB1\/CENPF axis contributes to gastric cancer proliferation and\n                    metastasis","volume":"11","author":"E B Chen","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"ref21","first-page":"1","article-title":"MicroRNA-144 inhibits cell proliferation, migration and invasion in human\n                    hepatocellular carcinoma by targeting CCNB1","volume":"19","author":"J Gu","year":"2019","journal-title":"Cancer Cell Int"},{"key":"ref22","first-page":"44","article-title":"Expression profiling of cyclin B1 and D1 in cervical carcinoma","volume":"28","author":"M Zhao","year":"2006","journal-title":"Exp Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3803\/EnM.2020.35.1.132","article-title":"Protein expression of cyclin B1, transferrin receptor, and fibronectin is\n                    correlated with the prognosis of adrenal cortical carcinoma","volume":"35","author":"S J Moon","year":"2020","journal-title":"Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"237.e1","DOI":"10.1016\/j.urolonc.2015.11.011","article-title":"The decrease of cyclin B2 expression inhibits invasion and metastasis of bladder\n                    cancer","volume":"34","author":"Cy Lei","year":"2016","journal-title":"Urol Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/03630242.2022.2106530","article-title":"CCNB2 expression correlates with worse outcomes in breast cancer patients: a\n                    pooled analysis","volume":"62","author":"C Sun","year":"2022","journal-title":"Women Health"},{"key":"ref26","first-page":"5511041","article-title":"Cyclin B2 (CCNB2) stimulates the proliferation of triple-negative breast cancer\n                    (TNBC) cells in vitro and in vivo","author":"S Wu","year":"2021","journal-title":"Dis Markers"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e0231665","DOI":"10.1371\/journal.pone.0231665","article-title":"CCNB2 and AURKA overexpression may cause atypical mitosis in Japanese\n                    cortisol-producing adrenocortical carcinoma with TP53 somatic variant","volume":"15","author":"A Ikeya","year":"2020","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1340-7","article-title":"ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by\n                    mediating miR-218-5p\/LASP1 signaling axis","volume":"38","author":"A Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3233\/CBM-160585","article-title":"Overexpression of Anillin (ANLN) is correlated with colorectal cancer\n                    progression and poor prognosis","volume":"16","author":"G Wang","year":"2016","journal-title":"Cancer Biomark"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1002\/cam4.5177","article-title":"Clinical implication and immunological landscape analyses of ANLN in pan-cancer:\n                    a new target for cancer research","volume":"12","author":"L Zhang","year":"2023","journal-title":"Cancer Med"},{"key":"ref31","first-page":"5322929","article-title":"Comprehensive analysis of ANLN in human tumors: a prognostic biomarker\n                    associated with cancer immunity","author":"X Zhang","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"922472","DOI":"10.3389\/fgene.2022.922472","article-title":"Pan-cancer analysis of the prognostic and immunological role of ANLN: an\n                    onco-immunological biomarker","volume":"13","author":"K Liu","year":"2022","journal-title":"Front Genet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.2147\/CMAR.S316599","article-title":"Role of Bclaf1 in promoting adrenocortical carcinoma proliferation: a study\n                    combining the use of bioinformatics and molecular events","volume":"13","author":"H Zhou","year":"2021","journal-title":"Cancer Manag Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/s12967-022-03641-y","article-title":"CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating\n                    epithelial\u2013mesenchymal transition, G2\/M phase transition, and\n                    PANoptosis","volume":"20","author":"L Ren","year":"2022","journal-title":"J Transl Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12967-022-03277-y","article-title":"CENPF\/CDK1 signaling pathway enhances the progression of adrenocortical\n                    carcinoma by regulating the G2\/M-phase cell cycle","volume":"20","author":"Yg Huang","year":"2022","journal-title":"J Transl Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbrc.2021.02.117","article-title":"CDK1 inhibitor controls G2\/M phase transition and reverses DNA damage\n                    sensitivity","volume":"550","author":"S Sunada","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.2147\/CMAR.S193793","article-title":"CDKN3 promotes tumor progression and confers cisplatin resistance via RAD51 in\n                    esophageal cancer","volume":"11","author":"J Wang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3727\/096504016X14772375848616","article-title":"Knockdown of cyclin-dependent kinase inhibitor 3 inhibits proliferation and\n                    invasion in human gastric cancer cells","volume":"25","author":"Y Li","year":"2017","journal-title":"Oncol Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/ijc.31173","article-title":"YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma\n                    by regulating the CDKN3\/MdM2\/P53\/P21 signaling\n                    pathway","volume":"142","author":"D Liu","year":"2018","journal-title":"Int J Cancer"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/bjc.2015.378","article-title":"Overexpression of major CDKN3 transcripts is associated with poor survival in\n                    lung adenocarcinoma","volume":"113","author":"C Fan","year":"2015","journal-title":"Br J Cancer"},{"key":"ref41","first-page":"3614","article-title":"CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1","volume":"24","author":"W H Li","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.7150\/jca.26698","article-title":"Identification of five genes as a potential biomarker for predicting progress\n                    and prognosis in adrenocortical carcinoma","volume":"9","author":"H Xiao","year":"2018","journal-title":"J Cancer"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.7150\/jca.29490","article-title":"KIAA0101 is a novel transcriptional target of FoxM1 and is involved in the\n                    regulation of hepatocellular carcinoma microvascular invasion by regulating\n                    epithelial-mesenchymal transition","volume":"10","author":"T Zhang","year":"2019","journal-title":"J Cancer"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"10633","DOI":"10.1038\/ncomms10633","article-title":"PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast\n                    cancer cell stemness","volume":"7","author":"X Wang","year":"2016","journal-title":"Nat Commun"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"e26866","DOI":"10.1371\/journal.pone.0026866","article-title":"KIAA0101 is overexpressed, and promotes growth and invasion in adrenal\n                    cancer","volume":"6","author":"M Jain","year":"2011","journal-title":"PLoS One"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.trecan.2017.11.002","article-title":"PRC1: linking cytokinesis, chromosomal instability, and cancer evolution","volume":"4","author":"J Li","year":"2018","journal-title":"Trends Cancer"},{"key":"ref47","first-page":"1","article-title":"Overexpression of protein regulator of cytokinesis 1 facilitates tumor growth\n                    and indicates unfavorable prognosis of patients with colon cancer","volume":"20","author":"T Xu","year":"2020","journal-title":"Cancer Cell Int"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/15384101.2022.2122258","article-title":"Expression of the cytokinesis regulator PRC1 results in p53-pathway activation\n                    in A549 cells but does not directly regulate gene expression in the nucleus","volume":"22","author":"S Hanselmann","year":"2023","journal-title":"Cell Cycle"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/gutjnl-2015-310625","article-title":"The microtubule-associated protein PRC1 promotes early recurrence of\n                    hepatocellular carcinoma in association with the Wnt\/\u03b2-catenin\n                    signalling pathway","volume":"65","author":"J Chen","year":"2016","journal-title":"Gut"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-017-0682-z","article-title":"Xi Gm et al. PRC1 contributes to tumorigenesis of lung adenocarcinoma in\n                    association with the Wnt\/\u03b2-catenin signaling pathway","volume":"16","author":"P Zhan","year":"2017","journal-title":"Mol Cancer"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"11161","DOI":"10.1038\/s41598-022-15205-7","article-title":"Oncogenic role and potential regulatory mechanism of topoisomerase II\u03b1\n                    in a pan-cancer analysis","volume":"12","author":"X Wang","year":"2022","journal-title":"Sci Rep"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1530\/ERC-17-0095","article-title":"Topoisomerase 2\u03b1 and thymidylate synthase expression in adrenocortical\n                    cancer","volume":"24","author":"E Roca","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/1878-0261.12457","article-title":"Mutual regulation of MDM 4 and TOP 2A in cancer cell proliferation","volume":"13","author":"T Liu","year":"2019","journal-title":"Mol Oncol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/ERC-12-0403","article-title":"TOP2A is overexpressed in and a therapeutic target for adrenocortical\n                    carcinoma","volume":"20","author":"M Jain","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"ref55","first-page":"1009","article-title":"TYMS-TM4SF4 axis promotes the progression of colorectal cancer by EMT and\n                    upregulating stem cell marker","volume":"12","author":"F Zhang","year":"2022","journal-title":"Am J Cancer Res"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/biomedicines10061267","article-title":"Thymidylate synthase overexpression drives the invasive phenotype in colon\n                    Cancer cells","volume":"10","author":"W M Ciszewski","year":"2022","journal-title":"Biomedicines"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41416-020-01095-x","article-title":"Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal\n                    transition in non-small cell lung cancer","volume":"124","author":"M A Siddiqui","year":"2021","journal-title":"Br J Cancer"},{"key":"ref58","first-page":"4667","article-title":"Screening and identification of key biomarkers in adrenocortical carcinoma based\n                    on bioinformatics analysis","volume":"18","author":"Z Xing","year":"2019","journal-title":"Oncol Lett"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3390\/ijms20092228","article-title":"A comprehensive bioinformatics analysis of UBE2C in cancers","volume":"20","author":"H Dastsooz","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/1541-7786.MCR-19-0561","article-title":"UBE2C is upregulated by estrogen and promotes epithelial\u2013mesenchymal\n                    transition via p53 in endometrial cancer","volume":"18","author":"Y Liu","year":"2020","journal-title":"Mol Cancer Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bbrc.2020.11.034","article-title":"UBE2C mRNA expression controlled by miR-300 and HuR determines its oncogenic\n                    role in gastric cancer","volume":"534","author":"Y Wang","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"ref62","first-page":"765772","article-title":"Comprehensive pan-cancer analysis of the prognostic and immunological roles of\n                    the METTL3\/lncRNA-SNHG1\/miRNA-140-3p\/UBE2C axis. Front\n                    Cell","volume":"9","author":"X Jiang","year":"2021","journal-title":"Develop Biol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"112623","DOI":"10.1016\/j.msec.2021.112623","article-title":"Doxorubicin nanoformulations on therapy against cancer: An overview from the\n                    last 10 years","volume":"133","author":"N A D\u2019Angelo","year":"2022","journal-title":"Biomat Adv"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.21037\/tlcr-22-225","article-title":"Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell\n                    lung cancer patients","volume":"11","author":"K Kushiro","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11060-018-2970-x","article-title":"Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus\n                    cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2\n                    trial","volume":"140","author":"J Wu","year":"2018","journal-title":"J Neurooncol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-018-0381-y","article-title":"Binding mechanism of anti-cancer chemotherapeutic drug mitoxantrone to DNA\n                    characterized by magnetic tweezers","volume":"16","author":"D Kreft","year":"2018","journal-title":"J Nanobiotechnol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.3390\/ijms21093203","article-title":"Synergy between photodynamic therapy and dactinomycin chemotherapy in 2D and 3D\n                    ovarian cancer cell cultures","volume":"21","author":"L Mohammad Hadi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2147\/IJN.S190027","article-title":"Idarubicin-loaded methoxy poly (ethylene glycol)-b-poly (l-lactide-co-glycolide)\n                    nanoparticles for enhancing cellular uptake and promoting antileukemia\n                    activity","volume":"14","author":"B Liang","year":"2019","journal-title":"Int J Nanomed"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"746114","DOI":"10.3389\/fgene.2021.746114","article-title":"Pegylated liposomal doxorubicin versus epirubicin as adjuvant therapy for stage\n                    I\u2013III breast cancer","volume":"12","author":"W Hu","year":"2021","journal-title":"Front Genet"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"104284","DOI":"10.1016\/j.phrs.2019.104284","article-title":"Lignans and neolignans: plant secondary metabolites as a reservoir of\n                    biologically active substances","volume":"146","author":"F Z\u00e1le\u0161\u00e1k","year":"2019","journal-title":"Pharmacol Res"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jmgm.2016.11.019","article-title":"Computational analysis of Amsacrine resistance in human topoisomerase II alpha\n                    mutants (R487K and E571K) using homology modeling, docking and all-atom\n                    molecular dynamics simulation in explicit solvent","volume":"72","author":"S Sader","year":"2017","journal-title":"J Mol Graph Model"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.talanta.2017.08.089","article-title":"Electrochemical monitoring of the interaction between anticancer drug and DNA in\n                    the presence of antioxidant","volume":"178","author":"M Muti","year":"2018","journal-title":"Talanta"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1586\/14737140.2015.1115350","article-title":"Valrubicin in refractory non-muscle invasive bladder cancer","volume":"15","author":"P Sharma","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/17474086.2020.1756257","article-title":"Pralatrexate injection for the treatment of patients with relapsed or refractory\n                    peripheral T-cell lymphoma","volume":"13","author":"C Z Jennifer","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and\n                    chemoresistance in pancreatic cancer","volume":"741","author":"L de Sousa Cavalcante","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14656566.2018.1560422","article-title":"Capecitabine for the treatment of pancreatic cancer","volume":"20","author":"N S Siddiqui","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ygyno.2020.08.018","article-title":"Reproductive outcomes after floxuridine-based regimens for gestational\n                    trophoblastic neoplasia: A retrospective cohort study in a national referral\n                    center in China","volume":"159","author":"F Jiang","year":"2020","journal-title":"Gynecol Oncol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"15352","DOI":"10.3390\/ijms232315352","article-title":"miR-145-5p Targets Sp1 in non-small cell lung cancer cells and links to BMI1\n                    induced pemetrexed resistance and epithelial\u2013mesenchymal transition","volume":"23","author":"W W Chang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1245\/s10434-018-6497-3","article-title":"The impact of metronomic adjuvant chemotherapy in patients with advanced oral\n                    cancer","volume":"25","author":"M Y Hsieh","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4062\/biomolther.2022.017","article-title":"Modulation of reactive oxygen species to overcome 5-fluorouracil resistance","volume":"30","author":"K S Chun","year":"2022","journal-title":"Biomol Ther (Seoul)"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/17843286.2020.1870855","article-title":"Joint Belgian recommendation on screening for DPD-deficiency in patients treated\n                    with 5-FU, capecitabine (and tegafur)","volume":"77","author":"V Casneuf","year":"2022","journal-title":"Acta Clin Belg"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbrc.2022.04.063","article-title":"Trifluridine induces HUVECs senescence by inhibiting mTOR-dependent\n                    autophagy","volume":"610","author":"H J Jia","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"ref83","first-page":"1","article-title":"Raltitrexed regulates proliferation and apoptosis of HGC-27 cells by\n                    upregulating RSK4","volume":"23","author":"C Hu","year":"2022","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.26508","article-title":"Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia:\n                    Phase 2, multicenter, open-label study","volume":"97","author":"D J Kuter","year":"2022","journal-title":"Am J Hematol"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2013.37","article-title":"Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor\n                    proliferation in patients with relapsed and refractory chronic lymphocytic\n                    leukemia","volume":"27","author":"S Herman","year":"2013","journal-title":"Leukemia"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2209-0771.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T16:29:03Z","timestamp":1730824143000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2209-0771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":85,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2024,7,30]]},"published-print":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2209-0771","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"type":"print","value":"0018-5043"},{"type":"electronic","value":"1439-4286"}],"subject":[],"published":{"date-parts":[[2023,12,18]]}}}